China approved Johnson & Johnson's tablets for launch to children with pulmonary arterial hypertension. This creates a new sales opportunity, though the source gives no trial results or sales estimate.
This lets Johnson & Johnson offer the treatment in China to children with pulmonary arterial hypertension. The source gives no trial results or sales estimate, so the size of any business gain is unknown.
Follow Johnson & Johnson (JNJ) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for JNJ